Clinical Trials

NCT Number: NCT05726292 Phase: PHASE2 Trial Summary: Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as h – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Chicago Acronym:

NCT Number: NCT05799248 Phase: PHASE3 Trial Summary: Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): MidLantic Urology Acronym:

NCT Number: NCT05939414 Phase: PHASE3 Trial Summary: The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after defini – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Novartis Pharmaceuticals Acronym: PSMA-DC

NCT Number: NCT04513717 Phase: Phase 3 Trial Summary: This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NRG Oncology Acronym:

NCT Number: NCT06437574 Phase: PHASE2 Trial Summary: To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Cedars-Sinai Medical Center Acronym:

NCT Number: NCT04519879 Phase: Phase 2 Trial Summary: This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back ( – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): City of Hope Medical Center Acronym:

NCT Number: NCT04729114 Phase: Phase 1|Phase 2 Trial Summary: A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cance – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Astellas Pharma Global Development, Inc. Acronym:

NCT Number: NCT04471727 Phase: Phase 1|Phase 2 Trial Summary: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab i – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, […]

NCT Number: NCT04557449 Phase: PHASE1|PHASE2 Trial Summary: This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Pfizer Acronym: CDK4i

NCT Number: NCT06378866 Phase: PHASE2 Trial Summary: This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Mayo Clinic Acronym: DIVINE